Learn more about our policy experts.

Media Contacts

Angela Bradbery, Director of Communications
w. (202) 588-7741
c. (202) 503-6768
abradbery@citizen.org, Twitter

Barbara Holzer, Broadcast Manager
w. (202) 588-7716

Karilyn Gower, Press Officer
w. (202) 588-7779

David Rosen, Press Officer, Regulatory Affairs
w. (202) 588-7742

Symone Sanders, Communications Officer, Global Trade Watch division
w. (202) 454-5108

Other Important Links

Press Release Database
Citizen Vox blog
Texas Vox blog
Consumer Law and Policy blog
Energy Vox blog
Eyes on Trade blog

Follow us on Twitter


Feb. 12, 2014

FDA Should Reject Drug for Preventing Blood Clots, Public Citizen Tells Advisory Committee

Unethical Trials Failed to Provide Substantial Evidence That Cangrelor Is Effective

WASHINGTON, D.C. – The U.S. Food and Drug Administration (FDA) should not approve cangrelor, a treatment designed to prevent blood clots during heart artery-clearing angioplasty and stenting procedures, Public Citizen said today.

Testifying today before the FDA’s Cardiovascular and Renal Drugs Advisory Committee, Dr. Michael Carome, director of Public Citizen’s Health Research Group, strongly urged the committee to reject cangrelor, which is made by The Medicines Company, because the clinical trials conducted to test the medication were poorly and unethically administered.

During the main clinical trial, many of the people in the control group received substandard care, and as a result, the trial failed to provide substantial evidence that the medication is effective relative to treatments recommended by expert guidelines, Carome said. For example, subjects randomly assigned to the control group received the drug clopidogrel. This medication is routinely given before cardiac stent procedures begin to prevent clot formation in the stent and heart attacks during the procedure. However, many subjects received the medication after the conclusion of the procedure, likely resulting in a larger number of clots and heart attacks in control subjects during or immediately after the stent procedure.

The fact that the subjects were given substandard care also made the trial unethical. In addition, the consent forms at some trial sites failed to adequately describe to subjects the risks of participating in the trial relative to guideline-recommended care or to inform subjects of alternative courses of treatment that might be more effective.

“The FDA’s own lead medical reviewer wrote a scathing review and recommended that the drug not be approved because he considered the three major trials to be insufficient to prove the drug’s effectiveness, as well as unethical,” Carome said. “Public Citizen agrees and urges the FDA to follow the recommendations of its most knowledgeable experts and reject the approval of this treatment.”

Read today’s testimony.


Copyright © 2015 Public Citizen. Some rights reserved. Non-commercial use of text and images in which Public Citizen holds the copyright is permitted, with attribution, under the terms and conditions of a Creative Commons License. This Web site is shared by Public Citizen Inc. and Public Citizen Foundation. Learn More about the distinction between these two components of Public Citizen.

Public Citizen, Inc. and Public Citizen Foundation


Together, two separate corporate entities called Public Citizen, Inc. and Public Citizen Foundation, Inc., form Public Citizen. Both entities are part of the same overall organization, and this Web site refers to the two organizations collectively as Public Citizen.

Although the work of the two components overlaps, some activities are done by one component and not the other. The primary distinction is with respect to lobbying activity. Public Citizen, Inc., an IRS § 501(c)(4) entity, lobbies Congress to advance Public Citizen’s mission of protecting public health and safety, advancing government transparency, and urging corporate accountability. Public Citizen Foundation, however, is an IRS § 501(c)(3) organization. Accordingly, its ability to engage in lobbying is limited by federal law, but it may receive donations that are tax-deductible by the contributor. Public Citizen Inc. does most of the lobbying activity discussed on the Public Citizen Web site. Public Citizen Foundation performs most of the litigation and education activities discussed on the Web site.

You may make a contribution to Public Citizen, Inc., Public Citizen Foundation, or both. Contributions to both organizations are used to support our public interest work. However, each Public Citizen component will use only the funds contributed directly to it to carry out the activities it conducts as part of Public Citizen’s mission. Only gifts to the Foundation are tax-deductible. Individuals who want to join Public Citizen should make a contribution to Public Citizen, Inc., which will not be tax deductible.


To become a member of Public Citizen, click here.
To become a member and make an additional tax-deductible donation to Public Citizen Foundation, click here.